Journal of Crohn s and Colitis · 2023 · 58 citations · 6 references
PharmacyInternal MedicinePharmacotherapyGastroenterologyGastrointestinal PharmacotherapyInflammationAcute InflammationCrohn Disease PharmacotherapyGastrointestinal InflammationInflammatory Bowel DiseaseResolution Of InflammationUlcerative Colitis PharmacotherapyAcute Severe Ulcerative ColitisBleedingClinical RemissionDurable Clinical ResponseInflammatory Bowel Disease TherapyInflammatory ColitisRefractory Ulcerative ColitisSalvage Combination Therapy
BACKGROUND AND AIMS: Acute severe ulcerative colitis [ASUC] is a medical emergency treated with intravenous steroids followed by infliximab or cyclosporin in the case of steroid failure with emergent colectomy required in refractory or severe cases. Case series have reported on the effectiveness of tofacitinib for refractory disease, but data regarding the effectiveness of upadacitinib in this setting have not been previously reported. We describe the use of upadacitinib therapy for steroid-refractory ASUC in patients with prior loss of response to infliximab. METHODS: Six patients who received upadacitinib for steroid-refractory ASUC were identified at two Australian tertiary inflammatory bowel disease centres. Patients were followed for up to 16 weeks after discharge with clinical, biochemical and intestinal ultrasound [IUS] outcomes. RESULTS: All six patients demonstrated clinical response to upadacitinib induction during their inpatient admission. Four patients achieved corticosteroid-free clinical remission by week 8, including complete resolution of rectal bleeding and transmural healing assessed by IUS, and sustained clinical remission at week 16. One patient proceeded to colectomy at week 15 due to refractory disease. No adverse events directly attributable to upadacitinib were identified. CONCLUSIONS: Upadacitinib may have a role as a safe and effective salvage therapy for steroid-refractory ASUC in patients who have previously failed to respond to infliximab therapy. Prospective studies are required to determine the safety and efficacy of upadacitinib use in this setting before routine use can be recommended.
6
Cortisone in Ulcerative Colitis
S. C. Truelove, L. J. Witts · BMJ · 1955 · 2.8K citations · Full text
Medicine, Immunology, Pathobiology +12
Predicting outcome in severe ulcerative colitis.
Simon Travis, J. Mark Farrant, Christopher J. Ricketts et al. · Gut · 1996 · 784 citations · Full text
Silvio Danese, Séverine Vermeire, Wen Zhou et al. · The Lancet · 2022 · 597 citations · Full text
Pharmacy, Oncology, Pharmacotherapy +10
Jeffrey Berinstein, Jessica L. Sheehan, Michael Dias et al. · Clinical Gastroenterology and Hepatology · 2021 · 130 citations · Full text